key: cord-0692863-7j0aeu9w authors: Albayrak, Ayse; Alay, Handan; Yilmaz, Sibel Iba title: Comorbidity of Crimean-Congo Hemorrhagic Fever and COVID-19 date: 2021-09-24 journal: Revista da Sociedade Brasileira de Medicina Tropical DOI: 10.1590/0037-8682-0429-2021 sha: bc1f1bceb6bd83d42a5b48c2b1e830808dc462bc doc_id: 692863 cord_uid: 7j0aeu9w nan Ayse Albayrak [1] , Handan Alay [1] and Sibel Iba Yilmaz [2] [1]. Ataturk University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Erzurum, Turkey. [2] . Republic of Turkey Ministry of Health, Erzurum City Hospital, Department of Infectious Diseases and Clinical Microbiology, Erzurum, Turkey. A 61-year-old woman presented to the emergency department with fever, weakness, headache, and cough that had persisted for one week. Her pulmonary saturation was 87%, and her hemogram, biochemistry, and bleeding parameters were normal. The pulmonary tomography report described 'several areas of linear atelectasis in the basal parts of both lungs'. The patient's SARS-CoV-2 polymerase chain reaction (PCR) test was positive, and she was started on low molecular weight heparin (LMWH) 0.6 mL/day and dexamethasone 6 mg/day therapy. On the fifth day of follow-up, her WBC was 2.97X10 3 /µL (lymphocyte count, 510); platelets, 45X10 3 / µL; aspartate-aminotransferase, 537 U/L; alanine aminotransferase, 341 U/L; lactate dehydrogenase, 590 U/L; ferritin, 1650 ng/mL; and D-dimer, 35,200 ng/mL. No shortness of breath or other respiratory symptoms were observed. However, she described having removed a tick from her body approximately a week before. Hematoma, diffuse ecchymosis, and bullous lesions developed on the left arm to which the LMWH had been administered (Figure 1A) . The patient's Crimean-Congo hemorrhagic fever (CCHF) PCR test results were positive. LMWH therapy was stopped, and supportive therapy was initiated for CCHF. The hematoma on the arm resolved during follow-up ( Figure 1B) . CCHF is a zoonotic viral disease endemic in Turkey. While diagnosis is relatively easy in patients with a tick bite history, it can be difficult in patients without one 1 . While CCHF progresses with hemorrhage, COVID-19 causes thrombosis 2 . Similar symptoms and laboratory findings can be seen in both diseases. CCHF must be considered in regions where it is endemic during the COVID-19 pandemic. Crimean-Congo hemorrhagic fever: an update COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET) The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. The author(s) received no financial support for the research, authorship, and/or publication of this article.Ayse Albayrak: 0000-0002-6177-4566Handan Alay: 0000-0002-4406-014X Sibel Iba Yilmaz: 0000-0002-4123-0828